3-[3-(溴甲基)苯基]噻吩 | 89929-85-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-[3-(溴甲基)苯基]噻吩
• 英文名称: 3-(3-bromomethylphenyl)thiophene
• 英文别名: 3-(thien-3-yl)benzyl bromide；3-(3-thienyl)benzyl bromide；3-[3-(Bromomethyl)phenyl]thiophene
• CAS: 89929-85-1
• 化学式: C₁₁H₉BrS
• 分子量: 253.162
• InChiKey: VCKUVGQHVFDLFU-UHFFFAOYSA-N

物化性质

• 熔点：
  69.5-70.5

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  C

反应信息

• 作为反应物：
  描述：

  3-[3-(溴甲基)苯基]噻吩 在 sodium chloride 、 potassium acetate 、 碳酸氢钠 作用下， 以 水 、 溶剂黄146 为溶剂， 生成 3-(thien-3-yl)phenylmethyl acetate
  参考文献：
  名称：

  Heterocyclic substituted benzyl alcohol, insecticidal ester derivatives,

  摘要：

  披露并举例说明了杀虫和杀螨的可选择取代的呋喃基苄基、噻吩基苄基、吡嗪基苄基或吡啶基苄基除虫酯，新型除虫醇和其他中间体，以及组合物，使用方法和酯类制备方法。

  公开号：

  US04426524A1
• 作为产物：
  描述：

  噻吩,3-(3-甲基苯基)- 在 N-溴代丁二酰亚胺(NBS) 、 sodium chloride 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 生成 3-[3-(溴甲基)苯基]噻吩
  参考文献：
  名称：

  Heterocyclic substituted benzyl alcohol, insecticidal ester derivatives,

  摘要：

  披露并举例说明了杀虫和杀螨的可选择取代的呋喃基苄基、噻吩基苄基、吡嗪基苄基或吡啶基苄基除虫酯，新型除虫醇和其他中间体，以及组合物，使用方法和酯类制备方法。

  公开号：

  US04426524A1

文献信息

• Substituted alkylamine derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05234946A1

  公开（公告）日：1993-08-10

  The substituted alkylamine derivatives represented by formula (I) ##STR1## wherein R.sup.1 represents (a) substituted or unsubstituted C.sub.2-6 alkenyl group, (b) substituted or unsubstituted C.sub.3-6 cycloalkenyl group, (c) substituted or unsubstituted C.sub.2-6 alkynyl group, (d) substituted or unsubstituted aryl group, (e) substituted or unsubstituted heterocyclic group, (f) fused heterocyclic group which may be substituted, or (g) group represented by the formula Ru.sup.11 -Ar wherein R.sup.11 is a heterocyclic group and Ar is a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and which may be substituted; ##STR2## represents a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and may be substituted by R.sup.7, X and Y are linking groups, R.sup.2 is H or lower alkyl, R.sup.3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl or lower cycloalkyl, R.sup.4 and R.sup.5 are independently hydrogen or halogen atoms, R.sup.6 represents (a) substituted or unsubstituted acyclic hydrocarbon group which may be unsaturated, (b) substituted or unsubstituted cycloalkyl group, or (c) substituted or unsubstituted phenyl group, or non-toxic salts thereof. (E)-N-(6-6-dimethyl-2-hepten-4-ynyl)-N-ethyl-3-[4-(3-thienyl)-2-thienyl-me thyloxy]benzylamine hydrochloride is a representative example. The substituted alkylamine derivatives are useful as pharmaceuticals, particularly for the treatment and prevention of hypercholesterolemia, hyperlipemia and arteriosclerosis.

  根据您的要求，以下是公式(I)所代表的取代烷基胺衍生物的中文翻译： “式中，R1 代表（a）取代或未取代的C2-6烯基团，（b）取代或未取代的C3-6环烯基团，（c）取代或未取代的C2-6炔基团，（d）取代或未取代的芳基团，（e）取代或未取代的杂环团，（f）可能被取代的融合杂环团，或（g）由公式Ru11-Ar表示的团，其中R11是杂环团，Ar是5或6成员的芳香环，其中可能含有杂N、O或S原子，并且可能被取代；##STR2##代表一个5或6成员的芳香环，其中可能含有杂N、O或S原子，并且可能被R7、X和Y是连接基团，R2是H或低级烷基，R3是氢、低级烷基、低级烯基、低级炔基或低级环烷基，R4和R5是独立的是氢或卤素原子，R6代表（a）可能是不饱和的取代或未取代的链状烃基团，（b）取代或未取代的环烷基团，或（c）取代或未取代的苯基团，或其非毒性的盐。以下是一个代表性的例子：(E)-N-(6-6-二甲基-2-庚烯-4-炔基)-N-乙基-3-[4-(3-噻吩基)-2-噻吩基甲氧基]苄胺盐酸盐。这些取代烷基胺衍生物作为药物很有用，特别适用于治疗和预防高胆固醇血症、高脂血症和动脉粥样硬化。”
• [EN] GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY<br/>[FR] COMPOSES MODULATEURS DE RECEPTEURS DE GLUCOCORTICOIDE ET PROCEDES
  申请人：LIGAND PHARM INC

  公开号：WO2005082909A1

  公开（公告）日：2005-09-09

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable derivatives thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also provided are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文提供了式（I）的化合物及其药用可接受的衍生物。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还提供了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病。
• Substituted amine derivatives having anti-hyperlipemia activity
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05439932A1

  公开（公告）日：1995-08-08

  Substituted amine derivatives represented by the general formula ##STR1## wherein Q is --C--D--E--F--G--M-- or --N--H--I--J--K--L-- [C, D, E, F, G, H, I, J, K and L are each O, S, a carbonyl group, --CHR.sup.a --, --R.sup.b .dbd. or --NR.sup.c -- (R.sup.a, R.sup.b and R.sup.c are each H or a lower alkyl group), M and N are each an aromatic ring of 5-6 members optionally having a halogen, OH, LN, a lower alkyl group or a lower alkoxy group, provided that L is not O, S, or --NR.sup.c --]; R is a heterocyclic ring of 5-6 members; R.sup.1 is H, a lower alkyl group, a lower haloalkyl group, a lower alkenyl group, a lower alkynyl group or a cycloalkyl group; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are each H, a halogen or a lower alkyl group or two of them denote a single bond; R.sup.8 and R.sup.9 are each F, CF.sub.3 or a lower alkyl group or are a cycloalkane in combination thereof; and R.sup.10 is H, F, CF.sub.3 an acetoxy group, a lower alkyl group or a lower alkoxy group. These compounds inhibit biosynthesis of cholesterol in mammals by inhibiting their squalene epoxidase, and thereby lower their blood cholesterol values. Therefore, these compounds are expected to be effective as an agent for treatment and prophylaxis of diseases caused by excess of cholesterol, for example, obesity, hyperlipemia and arteriosclerosis and heart and encephalic diseases accompanying them.

  通式为##STR1##的取代胺衍生物，其中Q为--C--D--E--F--G--M--或--N--H--I--J--K--L-- [C，D，E，F，G，H，I，J，K和L分别为O，S，羰基，--CHR.sup.a--，--R.sup.b .dbd.或--NR.sup.c--（R.sup.a，R.sup.b和R.sup.c分别为H或较低的烷基），M和N分别为5-6个成员的芳香环，可选地具有卤素，OH，LN，较低的烷基或较低的烷氧基，前提是L不是O，S或--NR.sup.c--]；R为5-6个成员的杂环环；R.sup.1为H，较低的烷基，较低的卤代烷基，较低的烯基，较低的炔基或环烷基；R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6和R.sup.7分别为H，卤素或较低的烷基或其中两个表示单键；R.sup.8和R.sup.9分别为F，CF.sub.3或较低的烷基或为环烷烃的组合；R.sup.10为H，F，CF.sub.3醋氧基，较低的烷基或较低的烷氧基。这些化合物通过抑制其角鲨烷环氧化酶来抑制哺乳动物中胆固醇的生物合成，从而降低它们的血液胆固醇值。因此，这些化合物预计可作为治疗和预防由胆固醇过多引起的疾病的药物，例如肥胖症，高脂血症，动脉硬化以及伴随它们的心脏和脑部疾病。
• Substituted amine derivatives having antihyperlipemia activity
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05306728A1

  公开（公告）日：1994-04-26

  Substituted amine derivatives represented by the general formula ##STR1## wherein Q is -C-D-E- F-G-M- or -N-H-I-J-K-L- [C, D, E, F, G, H, I, J, K and L are each O, S, a carbonyl group, -CHR.sup.2 -, -R.sup.b = or -NR.sup.c - (R.sup.a, R.sup.b and R.sup.c are each H or a lower alkyl group), M and N are each an aromatic ring of 5-6 members optionally having a halogen, OH, LN, a lower alkyl group or a lower alkoxy group, provided that L is not O, S, or -NR.sup.c -]; R is a heterocyclic ring of 5-6 members; R.sup.1 is H, a lower alkyl group, a lower haloalkyl group, a lower alkenyl group, a lower alkynyl group or a cycloalkyl group; R.sup.2, R.sup.3, R.sup.4, R.sup.5 R.sup.6 and R.sup.7 are each H, a halogen or a lower alkyl group or two of them denote a single bond; R.sup.8 and R.sup.9 are each F, CF.sub.3 or a lower alkyl group or are a cycloalkane in combination thereof; and R.sup.10 is H, F, CF.sub. 3 an acetoxy group, a lower alkyl group or a lower alkoxy group. These compounds inhibit biosynthesis of cholesterol in mammals by inhibiting their squalene epoxidase, and thereby lower their blood cholesterol values. Therefore, these compounds are expected to be effective as an agent for treatment and prophylaxis of diseases caused by excess of cholesterol, for example, obesity, hyperlipemia and arteriosclerosis and heart and encephalic diseases accompanying them.

  通式为##STR1##的取代胺衍生物，其中Q为-C-D-E-F-G-M-或-N-H-I-J-K-L- [C，D，E，F，G，H，I，J，K和L分别为O，S，羰基，-CHR.sup.2-，-R.sup.b=或-NR.sup.c-（R.sup.a，R.sup.b和R.sup.c分别为H或较低的烷基），M和N分别为5-6个成员的芳香环，可选地具有卤素，OH，LN，较低的烷基或较低的烷氧基，前提是L不是O，S或-NR.sup.c-]；R为5-6个成员的杂环环；R.sup.1为H，较低的烷基，较低的卤代烷基，较低的烯基，较低的炔基或环烷基；R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6和R.sup.7分别为H，卤素或较低的烷基或其中两个表示单键；R.sup.8和R.sup.9分别为F，CF.sub.3或较低的烷基或它们的环烷烃组合；R.sup.10为H，F，CF.sub.3乙酰氧基，较低的烷基或较低的烷氧基。这些化合物通过抑制它们的角鲨烷环氧化酶抑制哺乳动物的胆固醇生物合成，从而降低它们的血液胆固醇值。因此，这些化合物被预计作为治疗和预防由胆固醇过多引起的疾病的药物是有效的，例如肥胖症，高脂血症和动脉硬化以及伴随它们的心脏和脑疾病。
• Glucocorticoid receptor modulator compounds and methods
  申请人：Zhi Lin

  公开号：US20070281959A1

  公开（公告）日：2007-12-06

  Disclosed herein are compounds of Formula I: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文公开了I式化合物及其药物可接受的盐、酯、酰胺和前药。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病的方法。